Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

British Regulators Want Avandia Yanked

By Drug Discovery Trends Editor | September 7, 2010

LONDON (AP) – GlaxoSmithKline’s controversial diabetes pill Avandia should be pulled from the U.K. market because of concerns that the drug can increase the risk of heart attacks, British drug regulators said.

The Medicines and Healthcare products Regulatory Agency (MHRA) said an independent panel of experts had advised it that the risks of Avandia outweigh its benefits, and that the drug should no longer be sold in Britain. The body said it had sent a letter to doctors in July advising them to consider alternative treatments.

The British Medical Journal also called for the immediate withdrawal of the drug, saying it should never have been licensed in the first place.

Avandia was approved by the European Medicines Agency in 2000 to help lower blood sugar levels in patients with type 2 diabetes. The drug is currently under review in Europe and the U.S., and European regulators are scheduled to meet Wednesday to decide Avandia’s future.

GSK maintained that its extensive research involving over 50,000 patients has showed that Avandia does not increase the overall risk of heart attack, stroke or death compared to other diabetes drugs.

“We continue to believe that Avandia is safe and effective when it is prescribed appropriately,” the London-based company said in a statement.

But the British Medical Journal was critical of both GSK’s research methods and the European approval process, outlining what were described as multiple problems associated with Avandia’s safety in a report published Monday.

In the U.S., the Food and Drug Administration has placed Avandia under scrutiny since 2007, when a study suggested that patients taking the drug were 43 percent more likely to experience heart attack than those taking other diabetes drugs or no diabetes medication.


Filed Under: Drug Discovery

 

Related Articles Read More >

Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority
Portrait photo of Pfizer EVP and Medtronic board member Lidia Fonseca
Medtronic appoints Pfizer EVP as independent board director

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50